Summary & Overview
HCPCS A9601: Flortaucipir F18 Injection, Diagnostic, 1 mCi
HCPCS Level II code A9601 designates Flortaucipir F 18 injection, a diagnostic radiopharmaceutical used in PET imaging to visualize tau protein pathology. Nationally, this code is relevant for neuroimaging programs, neurologists, nuclear medicine physicians, and imaging facilities as the use of tau-targeted PET agents expands clinical and research applications in neurodegenerative disease evaluation. Payers frequently assess coverage policies for novel radiotracers based on clinical evidence, indication-specific utility, and cost considerations.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what A9601 represents, typical sites of service, and the clinical context for use in PET neuroimaging. The report highlights benchmark themes such as coverage variability, prior authorization trends, and coding nuances relevant to billing teams and revenue cycle staff. It also summarizes policy developments affecting radiopharmaceutical reimbursement and operational considerations for imaging centers. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code A9601 represents Flortaucipir F 18 injection, diagnostic, 1 millicurie. This code describes a radiopharmaceutical diagnostic injection used to image tau protein aggregates with positron emission tomography (PET). The service type is diagnostic radiopharmaceutical administration for PET imaging. The typical site of service is an outpatient imaging center or hospital-based imaging department.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult referred to a PET imaging center from a neurology clinic for evaluation of suspected Alzheimer disease or other tauopathies. The patient presents with progressive memory decline, impaired executive function, or atypical cognitive symptoms after initial clinical assessment and cognitive testing. Prior workup often includes neurologic examination, neuropsychological testing, MRI of the brain to assess structural changes, and basic laboratory testing to exclude reversible causes. The ordering neurologist documents the medical necessity for targeted molecular imaging to visualize cerebral tau protein deposition.
On the day of service the patient checks in to an outpatient nuclear medicine or radiology department (typical site of service: outpatient hospital radiology or freestanding imaging center). A nuclear medicine technologist and a radiopharmacist prepare the A9601 radiotracer (flortaucipir F 18) dose measured in millicuries. The patient is screened for contraindications, informed consent is obtained, and an IV line is established. The tracer A9601 is administered intravenously per protocol. After an appropriate uptake period, the patient undergoes a PET/CT acquisition of the brain. Images are interpreted by a board-certified neuroradiologist or nuclear medicine physician, who generates a report describing the pattern and degree of tau tracer uptake relative to normal reference regions. The study results are used by the ordering clinician to support diagnostic formulation, prognosis, and care planning for neurodegenerative disease management.
Coding Specifications
| Modifier | Description | When to Use |
|---|